Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.

<h4>Aim</h4>Investigate the cost and effects of a single-pill versus two- or three pill first-line antiretroviral combinations in reducing viral load, increasing CD4 counts, and first-line failure rate associated with respective regimens at 6 and 12 months.<h4>Methods</h4>Pat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Eduard J Beck, Sundhiya Mandalia, Roshni Sangha, Mike Youle, Ray Brettle, Mark Gompels, Margaret Johnson, Anton Pozniak, Achim Schwenk, Stephen Taylor, John Walsh, Ed Wilkins, Ian Williams, Brian Gazzard, NPMS-HHC Steering Group
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2012
Materias:
R
Q
Acceso en línea:https://doaj.org/article/522a57f424db4fd19a4e14c6ab92e719
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:522a57f424db4fd19a4e14c6ab92e719
record_format dspace
spelling oai:doaj.org-article:522a57f424db4fd19a4e14c6ab92e7192021-11-18T08:10:42ZLower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.1932-620310.1371/journal.pone.0047376https://doaj.org/article/522a57f424db4fd19a4e14c6ab92e7192012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23118869/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Aim</h4>Investigate the cost and effects of a single-pill versus two- or three pill first-line antiretroviral combinations in reducing viral load, increasing CD4 counts, and first-line failure rate associated with respective regimens at 6 and 12 months.<h4>Methods</h4>Patients on first-line TDF+3TC+EFV, TDF+FTC+EFV, Truvada®+EFV or Atripla® between 1996-2008 were identified and viral load and CD4 counts measured at baseline, six and twelve months respectively. Factors that independently predicted treatment failure at six and twelve months were derived using multivariate Cox's proportional hazard regression analyses. Use and cost of hospital services were calculated at six and twelve months respectively.<h4>Results</h4>All regimens reduced viral load to below the limit of detection and CD4 counts increased to similar levels at six and twelve months for all treatment regimens. No statistically significant differences were observed for rate of treatment failure at six and twelve months. People on Atripla® generated lower healthcare costs for non-AIDS patients at £5,340 (£5,254 to £5,426) per patient-semester and £9,821 (£9,719 to £9,924) per patient-year that was £1,344 (95%CI £1,222 to £1,465) less per patient-semester and £1,954 (95%CI £1,801 to £2,107) less per patient-year compared with Truvada®+EFV; healthcare costs for AIDS patients were similar across all regimens.<h4>Conclusion</h4>The single pill regimen is as effective as the two- and three-pill regimens of the same drugs, but if started as first-line induction therapy there would be a 20% savings on healthcare costs at six and 17% of costs at twelve months compared with Truvada®+EFV, that generated the next lowest costs.Eduard J BeckSundhiya MandaliaRoshni SanghaMike YouleRay BrettleMark GompelsMargaret JohnsonAnton PozniakAchim SchwenkStephen TaylorJohn WalshEd WilkinsIan WilliamsBrian GazzardNPMS-HHC Steering GroupPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 10, p e47376 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Eduard J Beck
Sundhiya Mandalia
Roshni Sangha
Mike Youle
Ray Brettle
Mark Gompels
Margaret Johnson
Anton Pozniak
Achim Schwenk
Stephen Taylor
John Walsh
Ed Wilkins
Ian Williams
Brian Gazzard
NPMS-HHC Steering Group
Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
description <h4>Aim</h4>Investigate the cost and effects of a single-pill versus two- or three pill first-line antiretroviral combinations in reducing viral load, increasing CD4 counts, and first-line failure rate associated with respective regimens at 6 and 12 months.<h4>Methods</h4>Patients on first-line TDF+3TC+EFV, TDF+FTC+EFV, Truvada®+EFV or Atripla® between 1996-2008 were identified and viral load and CD4 counts measured at baseline, six and twelve months respectively. Factors that independently predicted treatment failure at six and twelve months were derived using multivariate Cox's proportional hazard regression analyses. Use and cost of hospital services were calculated at six and twelve months respectively.<h4>Results</h4>All regimens reduced viral load to below the limit of detection and CD4 counts increased to similar levels at six and twelve months for all treatment regimens. No statistically significant differences were observed for rate of treatment failure at six and twelve months. People on Atripla® generated lower healthcare costs for non-AIDS patients at £5,340 (£5,254 to £5,426) per patient-semester and £9,821 (£9,719 to £9,924) per patient-year that was £1,344 (95%CI £1,222 to £1,465) less per patient-semester and £1,954 (95%CI £1,801 to £2,107) less per patient-year compared with Truvada®+EFV; healthcare costs for AIDS patients were similar across all regimens.<h4>Conclusion</h4>The single pill regimen is as effective as the two- and three-pill regimens of the same drugs, but if started as first-line induction therapy there would be a 20% savings on healthcare costs at six and 17% of costs at twelve months compared with Truvada®+EFV, that generated the next lowest costs.
format article
author Eduard J Beck
Sundhiya Mandalia
Roshni Sangha
Mike Youle
Ray Brettle
Mark Gompels
Margaret Johnson
Anton Pozniak
Achim Schwenk
Stephen Taylor
John Walsh
Ed Wilkins
Ian Williams
Brian Gazzard
NPMS-HHC Steering Group
author_facet Eduard J Beck
Sundhiya Mandalia
Roshni Sangha
Mike Youle
Ray Brettle
Mark Gompels
Margaret Johnson
Anton Pozniak
Achim Schwenk
Stephen Taylor
John Walsh
Ed Wilkins
Ian Williams
Brian Gazzard
NPMS-HHC Steering Group
author_sort Eduard J Beck
title Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
title_short Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
title_full Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
title_fullStr Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
title_full_unstemmed Lower healthcare costs associated with the use of a single-pill ARV regimen in the UK, 2004-2008.
title_sort lower healthcare costs associated with the use of a single-pill arv regimen in the uk, 2004-2008.
publisher Public Library of Science (PLoS)
publishDate 2012
url https://doaj.org/article/522a57f424db4fd19a4e14c6ab92e719
work_keys_str_mv AT eduardjbeck lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT sundhiyamandalia lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT roshnisangha lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT mikeyoule lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT raybrettle lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT markgompels lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT margaretjohnson lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT antonpozniak lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT achimschwenk lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT stephentaylor lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT johnwalsh lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT edwilkins lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT ianwilliams lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT briangazzard lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
AT npmshhcsteeringgroup lowerhealthcarecostsassociatedwiththeuseofasinglepillarvregimenintheuk20042008
_version_ 1718422105049006080